Screener
Denali Therapeutics Inc. DNLI Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $201,530 | $205,326 |
| Short-term marketable securities | 508,941 | 662,553 |
| Accounts receivable, net | 3,927 | — |
| Inventory | 4,139 | — |
| Prepaid expenses and other current assets | 35,390 | 32,779 |
| Total current assets | 753,927 | 900,658 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s short-term investments?
- Denali Therapeutics Inc. (DNLI) reported short-term investments of $508.94M in Q2 2026.
- How has Denali Therapeutics Inc.'s short-term investments changed year-over-year?
- Denali Therapeutics Inc.'s short-term investments decreased by 32.8% year-over-year, from $757.75M to $508.94M.
- What is the long-term trend for Denali Therapeutics Inc.'s short-term investments?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s short-term investments has grown at a -7.2% compound annual growth rate (CAGR), from $962.55M to $662.55M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Denali Therapeutics Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude